



INSTITUTIONAL BIOSAFETY COMMITTEE

UNIVERSITY of WASHINGTON

Meeting Minutes

Date: Wednesday, December 13, 2017

Time: 10:00 AM – 12:00 PM

Location: Foegen N-130A

- Members Present:**
1. Thea Brabb, Comparative Medicine (*Animal Containment Expert*)
 2. Lesley Colby, Comparative Medicine (*Animal Containment Expert*)
 3. Richard Grant, Washington National Primate Research Center
 4. Garry Hamilton (*Community Member*)
 5. Kevin Hybiske, Allergy and Infectious Diseases
 6. David Koelle, Allergy and Infectious Diseases
 7. Stephen Libby, Laboratory Medicine (*IBC Chair*)
 8. Matthew R. Parsek, Microbiology
 9. Jason Smith, Microbiology (*IBC Vice Chair*)
 10. Paul Swenson, Seattle-King Co. Dept. of Public Health (*Community Member*)

Commonly Used Abbreviations

IBC: Institutional Biosafety Committee

BSO: Biological Safety Officer

BUA: Biological Use Authorization

BSL: biosafety level

PI: Principal Investigator

IACUC: Institutional Animal Care and Use Committee

NIH: National Institutes of Health

DURC: Dual Use Research of Concern

SOP: standard operating procedure

1. **CALL TO ORDER:** The Institutional Biosafety Committee (IBC) Chair called the meeting to order at 10:03 am. A quorum was present.
2. **REMINDER:** The IBC Chair reminded attendees that any notes that they retain are subject to public disclosure. A statement was also made about conflict of interest and voting on research proposals as described in the IBC Charter. This includes sharing a grant or a familial relationship.
3. **APPROVAL OF MINUTES:**
 - The IBC Chair sought a motion to approve the minutes from the November 15, 2017 meeting.
 - A member made a motion to approve the November 15, 2017 minutes. Another member seconded the motion.
 - The committee voted unanimously to approve the November 15, 2017 meeting minutes.
4. **OLD BUSINESS:**
 - At the April meeting, Dr. Hybiske's BUA was approved pending receipt of NIH approval for Chlamydia strains falling under section III-A of the NIH guidelines. The NIH approval was received. The SOPs are being reviewed by the biosafety officer.
 - At the August IBC meeting, Dr. Davis's project was approved pending the biosafety officer's review of the IACUC amendment. The IACUC amendment has not yet been submitted.
 - At the November IBC meeting, Dr. Mougous's project was approved pending the lab inspection. The lab was inspected and no deficiencies were found. The BUA letter was sent.
 - At the November IBC meeting, Dr. Jay Neitz's project was approved pending the lab inspection. The lab was inspected and no deficiencies were found. The BUA letter was sent.
 - At the November IBC meeting, Dr. Maureen Neitz's project was approved pending the lab inspection. The lab was inspected and no deficiencies were found. The BUA letter was sent.
 - At the November IBC meeting, Dr. Singh's project was approved pending completion of the PI's biosafety training and submission of the IACUC protocol. The BUA letter was sent.
 - At the November IBC meeting, Dr. Skerrett's project was approved pending the lab inspection. The lab was inspected and no deficiencies were found. The BUA letter was sent.
 - At the November IBC meeting, Dr. Stayton's project was approved pending completion of the PI's biosafety training and the lab inspection. The training is still outstanding.
 - At the November IBC meeting, Dr. Murry's project was approved pending submission of the IACUC protocol. This is still pending.
5. **BIOSAFETY OFFICER (BSO) REPORT:** The Biosafety Officer Report includes (1) projects involving recombinant or synthetic nucleic acids covered under section III-E and III-F of the *NIH Guidelines*, (2) proposals involving non-recombinant biohazardous agents requiring BSL-1 and BSL-2 containment, and (3) administrative updates, such as room additions.
 - a. Biosafety Officer Report
 - Dr. Furlong and Dr. Chung each received a new BUA for *Mycobacterium bovis* (BCG strain) and *Staphylococcus aureus* used in vitro.
 - Dr. Thompson renewed a BUA involving human plasma and cells.
 - Dr. Gao received a new BUA for human cells.
 - Dr. McLean added a new room to his BUA approval.
 - Dr. Giltiy received a new BUA for human cells.

- Dr. Disis added some non-recombinant *Streptococcus* strains and non-recombinant *Mycobacterium aurum*.
- Dr. Theberge added *Mycobacterium bovis* (BCG strain) to her BUA letter.
- Dr. Van Voorhis added a new non-recombinant *Plasmodium chaubadi* strain.
- Dr. Hajjar added non-recombinant *Bacteroides xylanisolvens* to her BUA approval.
- Dr. Zheng and Dr. Chen each added the cell analysis facility to their BUA approvals.
- Dr. Doty added four Risk Group 1 fungal strains to her BUA approval.
- Dr. Grant added a baboon cell line that expresses baboon herpesvirus papio. The committee discussed the nomenclature and biosafety level for this agent. The committee would like the biosafety officer to clarify whether the alpha or gamma strain will be used, and whether there is an updated nomenclature system that should be used on the BUA letter.
- The IBC Chair sought a motion to approve this month's Biosafety Officer Report.
- A member made a motion to approve this month's Biosafety Officer Report. Another member seconded the motion.
- The Committee unanimously voted to approve this month's Biosafety Officer Report.

6. INDIVIDUAL PROJECT REVIEWS

1. Abkowitz, Janis, renewal, *The role of FLVCR in hematopoiesis and iron homeostasis*
 - The assigned IBC Primary Reviewer presented the Primary Review.
 - This is a renewal. The lab studies red cell differentiation.
 - A variety of gammaretroviral vectors are used on the project. Lentiviral vectors and feline leukemia virus is also used.
 - The lab inspection was completed with no deficiencies found. The training needs to be retaken.
 - The draft BUA letter was shown.
 - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Abkowitz.
 - The Committee voted unanimously to approve the draft BUA for Dr. Abkowitz., pending completion of the PI's biosafety training.
2. Buckner, Frederick, change, *Buckner antiparasitic and antibacterial drug discovery*
 - The assigned IBC Primary Reviewer presented the Primary Review.
 - This is a change request to add *Streptococcus pyogenes* both in vitro and in mice.
 - The inspection was completed and no deficiencies were noted. All of the required trainings were completed.
 - The draft BUA letter was shown.
 - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Buckner.
 - The Committee voted unanimously to approve the draft BUA for Dr. Buckner.
3. Garden, Gwenn, change, *Cell-Cell Communication in Neurodegeneration*
 - The assigned IBC Primary Reviewer presented the Primary Review.
 - This is a change request to add gammaretroviral vectors in mice. The vectors are ecotropic and will be used at ABSL-1.
 - The draft BUA letter was shown.

- An inspection was not required for this change because the lab has recently been inspected. All of the required trainings have been completed.
 - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Garden.
 - The Committee voted unanimously to approve the draft BUA for Dr. Garden.
4. Hajjar, Adeline, change, *Linking Innate and Adaptive Immunity*
- The assigned IBC Primary Reviewer presented the Primary Review.
 - This is a change request to add recombinant *Bacteroides xyloxylophilus*. This agent will be administered to germ-free mice.
 - An inspection was not required for this change because the lab has recently been inspected. All of the required trainings have been completed.
 - The draft BUA letter was shown.
 - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Hajjar.
 - The Committee voted unanimously to approve the draft BUA for Dr. Hajjar.
5. Hybiske, Kevin, change, *Chlamydia pathogenesis and immune evasion*
- One member declared a conflict of interest.
 - The assigned IBC Primary Reviewer presented the Primary Review.
 - This is a change request to add avirulent *Coxiella burnetii*. This requested strain is the phase II Nine Mile strain. This is an attenuated strain that has lost the genes for the virulence determinant lipopolysaccharide. This strain is exempt from federal select agent regulations.
 - An inspection was not required for this change because the lab has recently been inspected. All of the required trainings have been completed.
 - The draft BUA letter was shown.
 - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Hybiske.
 - The Committee voted unanimously, with one abstention, to approve the draft BUA for Dr. Hybiske.
6. Iritani, Brian, renewal, *Gene Function in Lymphopoiesis and Cancer*
- The assigned IBC Primary Reviewer presented the Primary Review.
 - This is a renewal. The lab is interested in understanding roles and mechanisms of the action of certain genes in immune cell development, function, and transformation.
 - Ecotropic gammaretroviral vectors with and without oncogenic inserts are used on the project. Lymphocytic choriomeningitis virus (strain Armstrong 53b) and vesicular stomatitis virus (VSV) are also used.
 - The lab was inspected and all deficiencies were corrected. All of the required trainings have been completed.
 - The draft BUA letter was shown.
 - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Iritani.
 - The Committee voted unanimously to approve the draft BUA for Dr. Iritani.
7. Jerome, Keith, new, *Understanding viral antibody resistance*
- The assigned IBC Primary Reviewer presented the Primary Review.
 - This is a new BUA application to study virus envelope gene evolution that allows escape from antibody neutralization.

- The investigators will culture, clone, and sequence several respiratory viruses: respiratory syncytial virus (RSV), human coronavirus (excluding SARS-CoV), human metapneumovirus, and human herpesvirus 6.
 - Third generation lentiviral vectors will also be used on the project.
 - The lab was inspected and all deficiencies were corrected. All of the required trainings have been completed.
 - The draft BUA letter was shown.
 - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Jerome.
 - The Committee voted unanimously to approve the draft BUA for Dr. Jerome.
8. Lee, Donghoon, renewal, *MR Methods for Small Animal Imaging*
- The assigned IBC Primary Reviewer presented the Primary Review.
 - This is a renewal. The goal of the project is to develop MRI methods to non-invasively monitor disease progression and therapy responses in transgenic mice that have undergone adeno-associated viral vector (AAV) gene therapy.
 - AAV is administered to mice under ABSL-1 conditions.
 - The draft BUA letter was shown.
 - The inspection was completed and no deficiencies were noted. All of the required trainings were completed.
 - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Lee.
 - The Committee voted unanimously to approve the draft BUA for Dr. Lee.
9. Savan, Ram, renewal, *Gene regulation of immune genes and the effect on immune responses*
- The assigned IBC Primary Reviewer presented the Primary Review.
 - This is a renewal. The goal of the research is to investigate the post-transcriptional regulatory elements involved in controlling immune gene dosage.
 - A variety of viruses will be used in vitro: Sendai virus, VSV, encephalomyocarditis virus, influenza A virus, and Coxsackie virus. *Listeria monocytogenes* and third-generation lentiviral vectors will also be used.
 - The draft BUA letter was shown.
 - The inspection was completed and no deficiencies were noted. All of the required trainings were completed.
 - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Savan.
 - The Committee voted unanimously to approve the draft BUA for Dr. Savan.
10. Woodward, Joshua, change, *Pathogenesis of Listeria monocytogenes and Staphylococcus aureus*
- The assigned IBC Primary Reviewer presented the Primary Review.
 - This is a change request to add recombinant strains of Salmonella Typhimurium and herpes simplex virus.
 - The committee discussed the recombinant herpes simplex virus and would like Dr. Woodward to provide more information about the nature of the strain's modifications.
 - The draft BUA letter was shown.
 - An inspection was not required for this change because the lab has recently been inspected. All of the required trainings have been completed.
 - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Woodward.

- The Committee voted unanimously to approve the draft BUA for Dr. Woodward, pending clarification of the recombinant herpes strain.

SUBCOMMITTEE REPORTS:

11. Shah, Javeed, change, *Immunology and Genetics of Infectious Diseases and Vaccines*

- Three members of the IBC served as the Subcommittee Reviewers. One of the Subcommittee Reviewers presented the Subcommittee Report.
- This is a change request to use *Mycobacterium tuberculosis* in a mouse model. Dr. Shah has already been approved to use *M. tuberculosis* in vitro use.
- The investigator will be working with a collaborator at the Center for Infectious Disease Research in Seattle. He will receive some training there. Dr. Shah will still receive all of the UW-specific standard required training to perform ABSL-3 research at UW. All SOPs will be reviewed by the biosafety officer.
- The draft BUA letter was shown.
- A member made a motion to approve the draft BUA letter for Dr. Shah. Another member seconded the motion.
- The Committee voted unanimously to approve the draft BUA for Dr. Shah.

12. Fuller, Deborah, change, *DNA Vaccine Therapy*

- Three members of the IBC served as the Subcommittee Reviewers. One of the Subcommittee Reviewers presented the Subcommittee Report.
- This is a change request to add three new strains of influenza for in vitro use. These are wildtype avian H2N2 and H2N3 strains. H2-containing viruses have not circulated in humans since the 1960s.
- The BMBL (Biosafety in Microbiological and Biomedical Laboratories) recommends BSL-3 containment and recent publications involving similar viruses align with this recommendation. The subcommittee agrees and recommends BSL-3 containment.
- The draft BUA letter was shown.
- A member made a motion to approve the draft BUA letter for Dr. Fuller. Another member seconded the motion.
- The Committee voted unanimously to approve the draft BUA for Dr. Fuller.

FOR YOUR INFORMATION:

- NIH Reportable Incident
 - A reportable incident involving a needlestick injury occurred on November 27th. The worker was performing general laboratory cleaning. While picking up plastic pipette tips on the floor, a hypodermic needle punctured the employee's thumb. It is unknown what experiment the particular needle was used for and when it may have been dropped on the floor. The laboratory uses needles involving research with a variety of mammalian cell lines including human cell lines transfected with liposomes with plasmid DNA expressing fluorescent proteins.
 - The employee scrubbed the site for 15 minutes and then was seen in the employee health clinic for counseling for potential blood borne pathogens.
 - Laboratory procedures were followed during the lab clean up with PPE including lab coat and gloves.

- A biosafety officer visited the laboratory and met with the PI to discuss the incident. A follow-up inspection was performed. The biosafety officer will be speaking with the entire lab about best practices for keeping a clean work environment and properly disposing of needles. Another follow-up lab inspection will be performed to ensure good laboratory practices and housekeeping are maintained.

ISSUES FROM THE FLOOR & PUBLIC COMMENTS:

There were no issues from the floor, and no public comments.

MEETING ADJOURNED AT APPROXIMATELY 11:59 a.m.